20 Oct 2023 --- Synthetic biology company Debut will be developing new bio-identical and novel fragrance molecules after receiving US$40 million in its Series B funding led by Bold, the venture capital fund of L’Oréal. Debut creates cosmetic bioactive ingredients using advanced biomanufacturing approaches, capable of producing fragrances that mimic natural and rare scents without leaving as much of an ecological footprint. The molecules exude “the same rich, full-bodied quality of naturals.”
